% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • chiraag_19 chiraag_19 Mar 20, 2013 10:07 AM Flag

    Will "sell on the news" hold true for Trius?

    Hi Kitty and Beav,

    Do you think Trius might see a sell off based on positive phase 3? I know analysts alongwith you have been pounding the table to buy but my biotech experience suggests otherwise. I bought at 6.07 mainly because I followed kitty around.

    I'm also holding Progenix and you should look into it. CEO bought a hell lot at around 2.6-2.7 and I still might add more if it falls below 4.5. What other stocks do you recommend? SNTS is looking way out of my reach now.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lately I've seen less investors holding through events and actually buying the event news on weakness at the open. For this company I believe a good run up will occur post results.

      To reduce risk through this particular event. I sold my position at $6.90 from $5.70. Still got 10K riding through the event from the upper $4's.

      I will add to the position post news if results are good.

    • afriendofthedevilsafriendofmine afriendofthedevilsafriendofmine Mar 20, 2013 10:42 AM Flag

      There is a lot of 'new' money in this stock that bought in the 4s. They could dampen any pop on good news. If there is any decline, or even a less than ten percent rise on good Ph III data, I would buy more if your horizon is more than a year. The risk in this drug is safety. Efficacy is well enough established. If there are no new side effects shown, this stock will find itself on a steady rise thru partnership deals, approval, and new indications before eventual buy-out north of 18.

      If you are a long term investor, buying on weakness after good results is a no brained. That's what big pharma does.

    • try SIGA for a judgement day reversal due in the next few days. When their vol. disappears it's usually a good indicator for a pop. TSRX may have a steady gain once phase lll is in. Like SIGA it has been fast tracked but unlike smallpox antiviral, TSRX's tedizolid is badly needed now. TSRX as a company has a good pipeline and started 2 yrs bfr SIGA went to court. Both SP are undervalued.

    • PGNX is a DOG. TSRX will fly on good news, hold up in this range, or slightly higher on neutral news and sell off if bad news. I don't think TRSK is that widely know, therefore plenty of institutions will need to buy if the data are strong enough to file for approval and there's a reasonable certainty of approval (stat sig- non inferior with lower side effects, less time).